{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:07:03Z","timestamp":1774566423643,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,20]]},"DOI":"10.7759\/cureus.101911","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T16:25:51Z","timestamp":1768926351000},"source":"Crossref","is-referenced-by-count":1,"title":["Rituximab-Induced Serum Sickness in Patients With Multiple Sclerosis: A Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Asmae","family":"Sikkal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salma","family":"Ouahmane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hicham","family":"El Otmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bouchra","family":"El Moutawakil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed Abdoh","family":"Rafai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S41645","article-title":"Rituximab for the treatment of rheumatoid arthritis: an update","volume":"8","author":"Mok CC","year":"2013","unstructured":"Mok CC. Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des Devel Ther. 2013, 8:87-100. 10.2147\/DDDT.S41645","journal-title":"Drug Des Devel Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.06.014","article-title":"Rituximab-induced serum sickness: a systematic review","volume":"45","author":"Karmacharya P","year":"2015","unstructured":"Karmacharya P, Poudel DR, Pathak R, et al.. Rituximab-induced serum sickness: a systematic review. Semin Arthritis Rheum. 2015, 45:334-40. 10.1016\/j.semarthrit.2015.06.014","journal-title":"Semin Arthritis Rheum"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101402","article-title":"Rituximab-induced serum sickness in multiple sclerosis patients","volume":"36","author":"Wolf AB","year":"2019","unstructured":"Wolf AB, Ryerson LZ, Pandey K, McGettigan BM, Vollmer T, Corboy JR, Alvarez E. Rituximab-induced serum sickness in multiple sclerosis patients. Mult Scler Relat Disord. 2019, 36:101402. 10.1016\/j.msard.2019.101402","journal-title":"Mult Scler Relat Disord"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/01.EWX.0000529795.14438.c1","article-title":"Correlations among insulin-like growth factor-1, homocysteine, vitamin B 12, and folic acid plasma levels following isotretinoin therapy in acne vulgaris patients","volume":"15","author":"Yosef A","year":"2018","unstructured":"Yosef A, Dawoud N, Gharib K. Correlations among insulin-like growth factor-1, homocysteine, vitamin B 12, and folic acid plasma levels following isotretinoin therapy in acne vulgaris patients. J Egypt Wom Dermatol Soc. 2018, 15:47-53. 10.1097\/01.EWX.0000529795.14438.c1","journal-title":"J Egypt Wom Dermatol Soc"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520910486","article-title":"A possible case of serum sickness after ocrelizumab infusion","volume":"27","author":"Moreira Ferreira VF","year":"2021","unstructured":"Moreira Ferreira VF, Kimbrough DJ, Stankiewicz JM. A possible case of serum sickness after ocrelizumab infusion. Mult Scler. 2021, 27:155-8. 10.1177\/1352458520910486","journal-title":"Mult Scler"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000000685","article-title":"Serum sickness following rituximab therapy in multiple sclerosis","volume":"9","author":"Holm\u00f8y T","year":"2019","unstructured":"Holm\u00f8y T, Fogdell-Hahn A, Svenningsson A. Serum sickness following rituximab therapy in multiple sclerosis. Neurol Clin Pract. 2019, 9:519-21. 10.1212\/CPJ.0000000000000685","journal-title":"Neurol Clin Pract"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517720044","article-title":"Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies","volume":"24","author":"Dunn N","year":"2018","unstructured":"Dunn N, Juto A, Ryner M, et al.. Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies. Mult Scler. 2018, 24:1224-33. 10.1177\/1352458517720044","journal-title":"Mult Scler"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","volume":"5","author":"Klein C","year":"2013","unstructured":"Klein C, Lammens A, Sch\u00e4fer W, et al.. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013, 5:22-33. 10.4161\/mabs.22771","journal-title":"MAbs"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2020.11.003","article-title":"Ocrelizumab can be used in multiple sclerosis after a rituximab-induced serum sickness: a case report","volume":"177","author":"Joubert M","year":"2021","unstructured":"Joubert M, Paris P, Clavelou P, Moisset X. Ocrelizumab can be used in multiple sclerosis after a rituximab-induced serum sickness: a case report. Rev Neurol (Paris). 2021, 177:1041-2. 10.1016\/j.neurol.2020.11.003","journal-title":"Rev Neurol (Paris)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005516","article-title":"Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study","volume":"90","author":"Bar-Or A","year":"2018","unstructured":"Bar-Or A, Grove RA, Austin DJ, et al.. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study. Neurology. 2018, 90:e1805-14. 10.1212\/WNL.0000000000005516","journal-title":"Neurology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/448854-rituximab-induced-serum-sickness-in-patients-with-multiple-sclerosis-a-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T16:25:52Z","timestamp":1768926352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/448854-rituximab-induced-serum-sickness-in-patients-with-multiple-sclerosis-a-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.101911","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,20]]}}}